Top Markets
Coin of the day
Mydecine Innovations Group Inc. Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc.

MYCO
Rang in Aktien #30738
Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise... Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise dedicated to advancing and commercializing therapies for a range of mental health conditions. The company specializes in developing treatments for specific populations, including veterans, emergency medical service providers, frontline workers, and individuals affected by post-traumatic stress disorder. It also operates Mindleap, an online telehealth platform offering mental wellness services and support for psychedelic integration, including aftercare. Furthermore, Mydecine engages in drug discovery, developing nature-derived psychedelic-assisted therapeutics, novel compounds, specific therapy protocols, and unique drug delivery systems. The company also manages a hemp cultivation facility in Pottus, Texas. Strategic collaborations include alliances with Leiden University Medical Center, Royal Ottawa Mental Health Centre, and LeadGen Labs for psychedelic drug development, as well as Applied Pharmaceutical Innovation for drug development and clinical trial programs. Founded in 2013, the company, originally known as NewLeaf Brands Inc., rebranded as Mydecine Innovations Group Inc. in June 2020 and is headquartered in Vancouver, Canada.
Aktienkurs
$0.25687791
Zuletzt synchronisiert: 2026-01-13
Marktkapitalisierung
$15.72M
Veränderung (1 Tag)
100.54%
Veränderung (1 Jahr)
6,975.98%
Land
CA
Handel Mydecine Innovations Group Inc. (MYCO)

Kategorie

P/B-Verhältnis für Mydecine Innovations Group Inc. (MYCO)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Mydecine Innovations Group Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Mydecine Innovations Group Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber